Skip to contentA
Axim Biotechnologies, Inc.
A
AXIMAxim Biotechnologies, Inc. Q2 2024 · 10-Q
Revenue$17.48K$17.48K+76.0% vs Q2 2023 Net Income-$2.27M-$2.27MN/M vs Q2 2023 EPS Diluted-$0.01-$0.01N/M vs Q2 2023 Gross Profit$15,735+58.5% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Axim Biotechnologies, Inc. · CIK 1514946 · Engraved from SEC EDGAR
Operating Cash Flowderived-$261,542N/M Margins · derivedGross margin90.0%−10.0 pt vs Q2 2023
Operating margin-3257.9%+3769.3 pt vs Q2 2023
Net margin-12986.0%+24513.2 pt vs Q2 2023
ended Jun 30, 2024 · filed Aug 19, 2024 · 50 d after period end